Head-to-head evidence
CD123 targeted CAR-NK cells vs SAR443579
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
CD123 targeted CAR-NK cells
Developed by Chongqing Precision Biotech Co., Ltd
NCT06006403 · Phase 1/2 · completed
This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
SAR443579
Developed by Sanofi
NCT05086315 · Phase 1/2 · terminated
This was an open-label, non-randomized, single-arm, first-in-human dose-escalation study of SAR443579 in relapsed or refractory acute leukemias and related blood cancers, with no control group. The primary goal was to find a safe dose by tracking dose-limiting toxicities, not to test efficacy, and the study was terminated before most of its planned expansion cohorts began.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CD123 targeted CAR-NK cells's landscape · SAR443579's landscape